Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -13.84% is 61% above its 5-year average of -35.86%, near the high end of its 5-year range (-77.97%–-13.84%).
37.85% above its 12-month average of -22.27%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.25%.
RETURN ON ASSETS (ROA)
-13.84%
RETURN ON ASSETS (ROA) AVG TTM
-22.27%
RETURN ON ASSETS (ROA) AVG 3Y
-29.75%
RETURN ON ASSETS (ROA) AVG 5Y
-35.86%
RETURN ON ASSETS (ROA) AVG 10Y
-31.54%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+37.85%
CURRENT VS 3Y AVG
+53.48%
CURRENT VS 5Y AVG
+61.40%
CURRENT VS 10Y AVG
+56.12%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
+48.55%
vs the sector median at left
Evolus, Inc.
Market Cap
$491.93M
Return on Assets (ROA)
-13.84%
TTM Avg
-22.27%
3Y Avg
-29.75%
5Y Avg
-35.86%
Market Cap
$491.55M
Return on Assets (ROA)
-3.84%
TTM Avg
-6.38%
3Y Avg
-6.57%
5Y Avg
-4.38%
Market Cap
$488.09M
Return on Assets (ROA)
-8.14%
TTM Avg
-30.20%
3Y Avg
-72.84%
5Y Avg
-64.85%
Market Cap
$483.26M
Return on Assets (ROA)
1.38%
TTM Avg
-14.74%
3Y Avg
-19.98%
5Y Avg
-18.10%
Market Cap
$484.56M
Return on Assets (ROA)
-22.99%
TTM Avg
-20.77%
3Y Avg
-18.00%
5Y Avg
-22.63%
Market Cap
$477.61M
Return on Assets (ROA)
-3.31%
TTM Avg
-8.72%
3Y Avg
-14.01%
5Y Avg
-17.66%
Market Cap
$468.31M
Return on Assets (ROA)
4.30%
TTM Avg
13.65%
3Y Avg
19.24%
5Y Avg
21.45%
Market Cap
$517.73M
Return on Assets (ROA)
-30.08%
TTM Avg
-46.42%
3Y Avg
-46.30%
5Y Avg
-37.15%
Market Cap
$548.99M
Return on Assets (ROA)
-89.18%
TTM Avg
-100.15%
3Y Avg
-92.96%
5Y Avg
-79.13%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $491.93M | -13.84% | -22.27% | -29.75% | -35.86% |
| NeoGenomics, Inc. (NEO)vs › | $491.55M | -3.84% | -6.38% | -6.57% | -4.38% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $488.09M | -8.14% | -30.20% | -72.84% | -64.85% |
| Arvinas, Inc. (ARVN)vs › | $483.26M | 1.38% | -14.74% | -19.98% | -18.10% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $484.56M | -22.99% | -20.77% | -18.00% | -22.63% |
| Cerus Corporation (CERS)vs › | $477.61M | -3.31% | -8.72% | -14.01% | -17.66% |
| NRC Health (NRC)vs › | $468.31M | 4.30% | 13.65% | 19.24% | 21.45% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $517.73M | -30.08% | -46.42% | -46.30% | -37.15% |
| Crescent Biopharma, Inc. (CBIO)vs › | $548.99M | -89.18% | -100.15% | -92.96% | -79.13% |
| Altimmune, Inc. (ALT)vs › | $525.08M | -17.40% | -49.85% | -45.66% | -41.17% |
ROA
-13.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -22.86% |
| 2024-12-31 | -21.68% |
| 2023-12-31 | -32.64% |
| 2022-12-31 | -41.81% |
| 2021-12-31 | -18.18% |
| 2020-12-31 | -77.97% |
| 2019-12-31 | -37.45% |
| 2018-12-31 | -27.27% |
| 2017-12-31 | -2.94% |
| 2016-12-31 | -25.89% |
| 2015-12-31 | -38.27% |
